AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024
2024年2月12日 · Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio; ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic ...
ImmunoGen is now part of AbbVie | AbbVie
ImmunoGen is now part of AbbVie Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.
AbbVie to Acquire ImmunoGen, including its Flagship Cancer …
2023年11月30日 · Under the terms of the transaction, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of approximately $10.1 billion. The boards of directors of both companies have approved the transaction.
AbbVie Completes Acquisition of ImmunoGen - Yahoo Finance
2024年2月12日 · With the completion of the acquisition, ImmunoGen is now part of AbbVie. "Together with ImmunoGen, we have the potential to continue redefining the standard of care for those living with...
AbbVie to Acquire ImmunoGen, including its Flagship Cancer …
immunogen is now part of abbvie Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.
AbbVie pays $10B to acquire ImmunoGen, doubling down on red …
2023年11月30日 · Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere.
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's …
2023年12月26日 · What does ImmunoGen bring to AbbVie? The time is right to expand AbbVie's business with its $10 billion acquisition of ImmunoGen (IMGN). ImmunoGen is a commercial-stage oncology company...
AbbVie to Acquire ImmunoGen, including its Flagship Cancer …
2023年11月30日 · Under the terms of the transaction, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of...
2023年11月30日 · • AbbVie has agreed to acquire all outstanding shares of ImmunoGen for a purchase price of $31.26 per share in all-cash transaction • Premium of approximately 95% to closing share price on November 29, 2023
Inside AbbVie's $10B buyout of ImmunoGen—and the bidding …
AbbVie is entering 2024 with a foothold in the antibody-drug conjugate (ADC) field thanks to its late-2023 buyout of ImmunoGen worth more than $10 billion. But according to a new securities...